ArticleSurgery today2026
Prognostic discrepancies between surgery-first and neoadjuvant-treated resected pancreatic cancer in the same pathological stage.
Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Redefining biologically borderline resectable pancreatic cancer: a data-driven reassessment of CA19-9 cutoff and a preoperative lymph node metastasis prediction model.Surgery today · 2026Article
- The post-neoadjuvant absolute lymphocyte count reflects the pathological response and local tumor control in pancreatic cancer.Surgery today · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare survival outcomes between patients undergoing upfront surgery and those receiving neoadjuvant therapy followed by surgery for pancreatic cancer stratified by pathological stage.
methodsWe retrospectively analyzed data from 456 patients who underwent curative-intent pancreatectomy between 2011 and 2023. The study patients were categorized into upfront surgery (n = 290) and neoadjuvant therapy (n = 166) groups. The overall and disease-free survival rates were compared between the groups within each pathological stage. Univariate and multivariate analyses were performed for patients with Stage I disease.
resultsIn Stage IA, overall and disease-free survival were significantly better in the upfront surgery group than in the neoadjuvant therapy group (P = 0.0022 and P = 0.0012, respectively). There were no significant differences between the groups in patients with Stage II disease. A multivariate analysis of patients with Stage I disease identified neoadjuvant therapy (HR: 4.053, P = 0.0010), biliary drainage (HR: 2.342, P = 0.0399), and absence of adjuvant chemotherapy (HR: 4.563, P = 0.0004) as independent predictors of poor overall survival.
conclusionEven within the same pathological stage, the survival outcomes differed between the upfront surgery and neoadjuvant therapy groups. These findings suggest that treatment history should be considered when interpreting the pathological stage and assessing the prognosis of patients with pancreatic cancer.
Indexed as
Identifiers
41196378What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.